Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil
Authors:
- 1 August 1997
- journal article
- clinical trial
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 123 (8) , 452-455
Abstract
On the basis of the overexpression of theMDR1 gene in human colorectal cancer, which may constitute a molecular basis for intrinsic drug resistance that can be reversed, and because of the limited therapeutic value of conventional cytotoxic treatment in this common disease, the present phase II study of P-glycoprotein-directed double modulation was initiated. Fifteen patients with measurable metastatic colorectal cancer, all of whom were refractory to first-line chemotherapy with 5-fluorouracil/leukovorin, were entered in this trial. Treatment consisted of 80 mg tamoxifen twice daily on days 1–9, oral dexverapamil every day on days 7–9, and 60 mg/m2 doxorubicin given by intravenous bolus injection on day 8. Courses were repeated every 4 weeks. After a median of three (between one and six) courses, none of the 14 evaluable patients had objective response, and 4 had stable disease. Adverse reactions consisted mainly of myelosuppression (WHO grade IV granulocytopenia was noted in 40%), and mild and reversible dexverapamil-related cardiovascular side-effects, specifically hypotension (47%). Our results suggest that, despite the histological demonstration of high levels of P-glycoprotein in colorectal cancer and administration of two potentially synergistic chemosensitizers, we were unsuccessful in circumventing its primary resistance to chemotherapy.Keywords
This publication has 25 references indexed in Scilit:
- Reversal of Multidrug Resistance by Transduction of Cytokine Genes Into Human Colon Carcinoma CellsJNCI: Journal of the National Cancer Institute, 1996
- P-Glycoprotein — A Marker of Cancer-Cell BehaviorNew England Journal of Medicine, 1995
- Chemosensitizers to Overcome and Prevent Multidrug Resistance?JNCI: Journal of the National Cancer Institute, 1995
- Resistance of Mammalian Tumor Cells to Inhibitors of DNA Topoisomerase II1994
- Phase II study of d-verapamil and doxorubicin in patients with metastatic colorectal cancerEuropean Journal of Cancer, 1993
- P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell linesInternational Journal of Cancer, 1991
- Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal AntibodyJNCI: Journal of the National Cancer Institute, 1991
- Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II studyCancer, 1990
- Zum Steroidhormonrezeptorenstatus kolorektaler KarzinomeOncology Research and Treatment, 1990
- Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.Proceedings of the National Academy of Sciences, 1986